VYVANSE® - new ADHD treatment option - now available in Canada |
| Tuesday, 02 February 2010 |
|
|
Friday, February 5, 2010
VYVANSE® - new ADHD treatment option - now available in Canada
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada. 
Subscribe to:
Post Comments (Atom)
VYVANSE® - new ADHD treatment option - now available in Canada |
| Tuesday, 02 February 2010 |
|
|
No comments:
Post a Comment